Anti-inflammatory drug shows promise for frailty in older adults
NCT ID NCT05727384
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether clazakizumab, an anti-inflammatory drug, could improve walking speed and reduce disability in older adults with frailty. 29 participants aged 70 and older received either the drug or a placebo every 4 weeks for 24 weeks. Researchers measured walking speed, physical function, and blood markers of inflammation to see if the drug made a difference.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Clazakizumab
What this could lead to
If it works, this could point toward a treatment that helps older adults with frailty walk faster and feel stronger by reducing inflammation.
What could go wrong
This is a small, early Phase 2 trial with only 29 participants, so results may not apply to everyone. The drug may not improve mobility or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pittsburgh, Health Studies Research Center
Pittsburgh, Pennsylvania, 15260, United States